| __timestamp | Incyte Corporation | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 347523000 | 47795223 |
| Thursday, January 1, 2015 | 479514000 | 50426000 |
| Friday, January 1, 2016 | 581861000 | 70853000 |
| Sunday, January 1, 2017 | 1326361000 | 78168000 |
| Monday, January 1, 2018 | 1197957000 | 123757000 |
| Tuesday, January 1, 2019 | 1154111000 | 140963000 |
| Wednesday, January 1, 2020 | 2215942000 | 131773000 |
| Friday, January 1, 2021 | 1458179000 | 210328000 |
| Saturday, January 1, 2022 | 1585936000 | 235780000 |
| Sunday, January 1, 2023 | 1627594000 | 244990000 |
| Monday, January 1, 2024 | 2606848000 |
Data in motion
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Incyte Corporation and Travere Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Incyte's R&D expenses surged by over 360%, peaking in 2020 with a remarkable 2.2 billion dollars. This reflects Incyte's aggressive strategy to maintain its edge in the pharmaceutical industry. In contrast, Travere Therapeutics, while showing a steady increase, expanded its R&D spending by approximately 410% over the same period, reaching nearly 245 million dollars in 2023. This growth underscores Travere's commitment to developing innovative therapies despite its smaller scale. The data highlights how both companies prioritize innovation, albeit at different scales, showcasing the diverse strategies within the biotech sector.
BeiGene, Ltd. vs Incyte Corporation: Strategic Focus on R&D Spending
Comparing Innovation Spending: Incyte Corporation and Viatris Inc.
R&D Insights: How Incyte Corporation and Amneal Pharmaceuticals, Inc. Allocate Funds
Incyte Corporation vs Soleno Therapeutics, Inc.: Strategic Focus on R&D Spending
Incyte Corporation or Vericel Corporation: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Incyte Corporation and Geron Corporation
Who Prioritizes Innovation? R&D Spending Compared for Incyte Corporation and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Travere Therapeutics, Inc.
Analyzing R&D Budgets: Verona Pharma plc vs Travere Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc.
Analyzing R&D Budgets: Travere Therapeutics, Inc. vs Xencor, Inc.